Overview
In recent years, while the fourth industrial revolution progresses, various new initiatives on innovation, which lead to novel values or substantial changes in healthcare product research & development, have begun by creation and usage of brand new ideas and technologies such as artificial intelligence, big data and utilization of medical and genome information.
There are two categories of innovation; disruptive innovation, which could bring drastic changes in the way we think and do things, and sustaining innovation, which could bring an improvement of products and services by using technology refinement in the existing platform. Important thing is that; we need to actively learn the cutting-edge technologies supporting various innovations, continuously think how our day-to-day work is going to change in the future, and create skills and mindset which could cope with various new changes. Meanwhile, we would like to encourage key stakeholders in healthcare to step back and think about if the values and changes brought by such innovations would really contribute to health and welfare of patients.
As the theme for the 17th DIA Japan Annual Meeting 2020, we chose the phrase “Beyond Innovation”. With DIA’s mission to provide a neutral platform for discussion, we would like to convene various stakeholder in Industry, government, academia as well as patients, to learn new technologies and initiatives, and discuss what we should eventually aiming for, leading to further facilitate the progress of healthcare innovation.
In this Annual Meeting, we are bringing a new change in the program development process as well; the sessions will be developed based on the submitted abstracts by DIA members, rather than developed by the program committee. We would like to develop a program with a totally new process where participants can openly discuss learnings and challenges based on the living experience of DIA members in healthcare research and development including case studies including successful ones as well as failures. Session themes in both specialties and cross-functional avenues by various stakeholders are greatly welcomed.
Let us realize attractive DIA Japan Annual Meeting by planning and implementing ideal sessions utilizing YOUR creative ideas. We will be waiting for your active participation!
Program Committee
-
Yuji Kumagai, MD, PhD • Professor, Clinical Research Center
Kitasato University Hospital, Japan -
Keiichi Inaizumi, MSc • Japan Clinical Project Manager, Clinical Operations and Compliance 1
Pfizer R&D Japan, Japan -
Taro Amagasaki, PhD • Head, Analytics Japan
Novartis Pharma K.K., Japan -
Nobuyuki Hanamura, PhD, MBA • Senior Director, Clinical Development Strategy & Solutions
IQVIA Services Japan K.K., Japan -
Toshiko Ishibashi, PhD, RN • Clinical Operation I, JAPAN, Clinical Operation
Ono Pharmaceutical Co., Ltd., Japan -
Kazuhiko Ishida, MSc, RPh • Risk Management Director, Pharmacovigilance
Astellas Pharma Inc., Japan -
Yayoi Kitawaki, MS • Senior Japan Program Head, Oncology Development Unit, Japan Development
Novartis Pharma K.K., Japan -
Yoshiko Komuro, PhD • Inspector Director, Office of Non-clinical and Clinical Compliance
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Takashi Moriya, PhD, MBA • Research & Development Division, Data Sciences, Director
Janssen Pharmaceutical K.K., Japan -
Sumimasa Nagai, MD, PhD • Senior Assistant Professor, Translational Research Center
The University of Tokyo Hospital, Japan -
Shinichi Nishiuma, MD • Executive Director, Head of Medical Affairs, Japan
Celgene K.K., Japan -
Mika Ogasawara • Quality Lead, Biometrics and Data Management
Pfizer R&D Japan, Japan -
Goshi Ozawa, MS • Exective officer, RWD dept.
Real World Data Co., Japan -
Keiko Tsumori • Associate Director, Medical Writing, Regulatory Affairs Area, Japan Development
MSD K.K., Japan -
Junichi Nishino, MSc, RPh • Director, Medical Regulatory Affairs Department
Otsuka Pharmaceutical Co., Ltd., Japan -
Hironobu Saito, PhD • Corporate Officer /Vice President, Oncology Clinical Development Dept., R&D Div.
Daiichi Sankyo Co., Ltd., Japan -
Junko Sato, PhD • Director, Office of International Programs
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Takashi Sato, MSc, PMP • Manager, Resource Management Group, R&D Planning Department
Kyowa Kirin Co., Ltd., Japan -
Atsushi Tsukamoto, PhD, MSc • Vice President, New Drug Regulatory Affairs
Daiichi Sankyo Co., Ltd., Japan
